Noxopharm Ltd. · ASX:NOX
Noxopharm — Shareholder Meeting (November 2022)
31 slides from Noxopharm's shareholder meeting presentation, Nov 17, 2022
Slide 1: Noxopharm 2022 AGM Corporate Presentation
Noxopharm 2022 AGM Corporate Presentation For personal use only Sydney, 17 November 2022: Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to release its 2022 AGM Corporate Presentation. Highlights: • Progress in Veyonda® clinical trials • Patient recruitment ongoing • Safety milest
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “pr
Slide 3: Noxopharm Limited AGM 2022
For personal use only NOXOPHARM LIMITED Delivering Science. Transforming Lives. AGM 2022 NOXOPHARM (ASX:NOX) DELIVERING SCIENCE. TRANSFORMING LIVES.
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for secu
Slide 5: Noxopharm - Dr Gisela Mautner, CEO & MD
For personal use only Noxopharm Dr Gisela Mautner CEO & MD
Slide 6: Noxopharm Overview
Noxopharm Overview For personal use only • Noxopharm is an innovative biotechnology company with a multi-platform strategy to advance the most promising life-saving therapies for patients with cancer or inflammatory diseases • It has grown to have three separate drug development programs: o Lead cli
Slide 7: Past Months – Highlights
Past 12 Months – Highlights Veyonda® For personal use only • Clinical trials progressing: • Patient recruitment ongoing and safety milestones being met • World-class clinical trial sites • Implemented more stringent quality assurance processes • Manufacturing increased and streamlined • Stable suppl
Slide 8: The Noxopharm Business Model
The Noxopharm Business Model Out-licensing For personal use only Upfront payment Proprietary and in-licenced Milestones drugs are advanced through Royalties drug development, with a view to out-licensing them at key value inflection points. Clinical Pre-Clinical Out-licensing Upfront payment Milesto
Slide 9: The Noxopharm Network
The Noxopharm Network For personal use only NOXOPHARM (ASX:NOX) - November 2022 7
Slide 10: Three Separate Therapy Development Programs
Three Separate Therapy Development Programs For personal use only Lead Candidate Innovative Technology Platforms Veyonda® ChromaTM SofraTM Clinical Phase 1 / 2 Trials Preclinical Studies NOXOPHARM (ASX:NOX) - November 2022 8
Slide 11: Veyonda
For personal use only Veyonda ® Noxopharm
Slide 12: Veyonda Combination Therapy Programs
Veyonda® Combination Therapy Programs For personal use only DARRT CEP IONIC (IIT*) External Beam Radiation Chemotherapy Immuno-oncology Therapy Working with top ranked cancer centres in the USA * IIT – investigator initiated trial NOXOPHARM (ASX:NOX) - November 2022 10
Slide 13: Veyonda Clinical Development
Veyonda® Clinical Development For personal use only Program Combination Indication Phase 1 Phase 2 Status DARRT-1 DARRT-1 manuscript in + Radiation DARRT-2 Active DARRT Prostate Cancer preparation; DARRT-2 Therapy Completed recruiting Results published Multiple Tumours CEP-1 Completed in CTR 2021 CE
Slide 14: DARRT-2 Trial – End-Stage Metastatic Cancers
DARRT-2 Trial – End-Stage Metastatic Cancers Status Update For personal use only • DARRT is a Phase 1b/2a trial examining the combination of Veyonda with low-dose radiotherapy for the treatment of • Currently in Part 1 – Dose-escalation; three dose cohorts have been tested with doses being escalated
Slide 15: CEP-2 Trial – Sarcoma
CEP-2 Trial – Sarcoma For personal use only Status Update • Phase 1, open-label, dose-escalation and dose-expansion study of Veyonda administered to cohorts of patients being treated • CEP-2 started in February 2022. with doxorubicin for metastatic soft tissue sarcoma. • First safety milestone passe
Slide 16: IONIC Trial – Checkpoint Inhibitors
IONIC Trial – Checkpoint Inhibitors For personal use only Status Update • Investigator-initiated trial. • IONIC is a pilot Phase 1 trial exploring the safety and efficacy • All sites now activated, and enrolment gaining momentum. signals of Veyonda® combined with the Bristol Myers Squibb checkpoint
Slide 17: Regulatory Engagement for Veyonda
Regulatory Engagement for Veyonda® For personal use only Orphan Drug Designation (ODD) Highly Valuable ODD Benefits • US Food and Drug Administration (FDA) granted ODD to Veyonda for soft ODD encourages the development of safe and effective tissue sarcoma – early 2022. treatments of rare diseases af
Slide 18: Chroma
For personal use only Chroma™ Noxopharm
Slide 19: Chroma Tech Platform
Cancer Inflammation CHROMA™ TECH PLATFORM Pancreatic Cancer TBK1/ Inflammation Brain Cancer — VS Other Cancers NOXOPHARM
Slide 20: Chroma Technology Platform – Preclinical Stage
ChromaTM Technology Platform – Preclinical Stage For personal use only Program Discovery Screening Preclinical Collaborators CRO-67 Pancreatic Cancer UNSW Sydney TBK1 inhibitors Cancer/Inflammation Hudson Institute of Medical Research Brain Cancer University of SA ChromaTM Undisclosed Cancer Noxopha
Slide 21: Chroma Pancreatic ductal adenocarcinoma (PDAC)
ChromaTM Pancreatic ductal adenocarcinoma (PDAC) For personal use only • PDAC is the fourth leading cause of cancer- related deaths in developed countries • 5-year survival rate of 8% from diagnosis1, ✓ Shared specific and novel bioactive properties minimal improvements in the past four decades ✓ Gr
Slide 22: Pancreatic Cancer Dual-Cell Therapy CRO-67
Pancreatic Cancer Dual-Cell Therapy CRO-67 For personal use only • Preclinical research in unique pancreatic cancer UNSW explant model. • CRO-67 attacks both pancreatic tumour cells and barrier cells surrounding the tumour. • Reducing the barrier exposes tumour to immune cells and to anti- cancer tr
Slide 23: Sofra
For personal use only Sofra™ Noxopharm
Slide 24: Sofra
SofraTM For personal use only ✓ Noxopharm has in-licensed a technology from Hudson Institute of Medical Research to create the Sofra™ technology platform, which is housed in Noxopharm’s subsidiary Pharmorage. ✓ This technology platform is based upon short nucleic acid sequences, the building blocks
Slide 25: Sofra Tech Platform
Stimulate Inflammatory Response Infectious Inflammatory Diseases SOFRA™ TECH PLATFORM Including Pharmorage Oligonucleotides targeting inflammatory sensors Cancer Neurodegenerative Diseases + Parkinson's Alzheimer's + Huntington's Multiple Sclerosis Cardiovascular Diseases _ yN + Hypertension NOXOPHA
Slide 26: Sofra – Market Opportunities
SofraTM – Market Opportunities For personal use only • Two main markets: • Chronic inflammatory conditions, including autoimmune diseases. • mRNA therapeutics, including vaccines. • Global immunology market is projected to grow from USD 92 billion in 2021 to USD 158 billion in 2028. • COVID-19 vacci
Slide 27: Financials and Business Outlook
For personal use only Noxopharm Financials and Business Outlook
Slide 28: Financial Summary
Financial Summary (ASX:NOX) For personal use only Capital Structure* Cash Position** Share price $0.15 Current Cash Holdings $9.9M Shares on issue 292M R&D rebate for 2021/22 $5M Market Capitalisation $42M Net capital raised1 $63.8M Govt grants/rebates received2 $23.5M * As at 11 Nov 2022 ** As at 3
Slide 29: 2023 Catalysts
2023 Catalysts For personal use only IONIC SofraTM Pancreatic Patent Safety / Preclinical Cancer Portfolio Interim Results Research Growth Efficacy Progress Results CEP-2 DARRT-2 Safety Results Safety Results Regulatory + Early Efficacy + Early Efficacy Engagement Signals Signals NOXOPHARM (ASX:NOX)
Slide 30: Closing Remarks
For personal use only Noxopharm Closing Remarks
Slide 31: Noxopharm Limited
For personal use only NOXOPHARM LIMITED Delivering Science. Transforming Lives. www.noxopharm.com NOXOPHARM (ASX:NOX) DELIVERING SCIENCE. TRANSFORMING LIVES.